Portal de Periódicos da CAPES

Outcome of SARS-CoV-2-Infected Polish Patients with Chronic Lymphocytic Leukemia

2022; Multidisciplinary Digital Publishing Institute; Volume: 14; Issue: 3 Linguagem: Inglês

10.3390/cancers14030558

2072-6694

Bartosz Puła, Katarzyna Pruszczyk, Ewa Pietrusza, Marta Morawska, Weronika Piszczek, Elżbieta Kalicińska, Agnieszka Szeremet, Jagoda Tryc-Szponder, Ewa Wąsik‐Szczepanek, Joanna Drozd‐Sokołowska, Helena Krzemień, Aleksandra Rejus, Małgorzata Gajewska, Kamil Wiśniewski, Maciej Wysocki, Alan Majeranowski, Ewa Paszkiewicz‐Kozik, Paweł Steckiewicz, Łukasz Szukalski, Łukasz Bołkuń, Monika Długosz‐Danecka, Krzysztof Giannopoulos, Krzysztof Jamroziak, Ewa Lech‐Marańda, Iwona Hus,

Chronic Lymphocytic Leukemia Research

The severe acute respiratory syndrome coronavirus (SARS-CoV-2) has become the cause of a worldwide pandemic, and its clinical infection course in patients with hematological malignancies may be severe.We performed a retrospective study on 188 chronic lymphocytic leukemia patients (CLL) with COVID-19 infection.At the time of infection 51 patients (27.1%) were treated with Bruton tyrosine kinase inhibitor (BTKi), 46 (24.5%) with anti-CD20 antibodies while 37 patients (19.7%) received venetoclax. In total, 111 patients (59.0%) required hospitalization and 50 patients (26.5%) died due to COVID-19. Patients with poor performance status (ECOG >1; p = 0.02), advanced age (>65 years; p = 0.04), low hemoglobin concentration (≤10 g/dl; p = 0.0001), low platelets (<100 × 109/L; p = 0.003), and elevated lactate dehydrogenase level (LDH; p = 0.014) had an increased risk of death due to COVID-19. Neither CLL treatment status (treatment naïve vs. treated) nor the type of CLL-directed treatment had impact on the SARS-CoV-2 related risk of death. The multivariate survival analysis showed that advanced age (p = 0.009) and low platelet count (p = 0.0001) were associated with significantly shorter patients' overall survival.SARS-CoV-2 infection in CLL patients is associated with poor outcome regardless of administered CLL-directed treatment.